Paul Graham Wyatt

This inventor holds 24 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Protein Kinase Inhibition. Top assignees: Astex Therapeutics Limited, Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2006-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Graham Wyatt. Retrieved from https://idiyas.com/inventor/paul-graham-wyatt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 6)

% Patents Active = 25.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 8.2

ph-index = 6

Forward Citations = 124(Granted Patents)

Location History:

Cambridge, GB (2006 - 2013)
Perth, GB (2010 - 2016)
Dundee, GB (2008 - 2017)

Company Filing History:

19 out of 126

Astex Therapeutics Limited

patents

7 out of 269

Cancer Research Technology Limited

patents

7 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

Smithkline Beecham Corporation

patents

where one patent can have more than one assignee

Years Active: 2006-2017

Loading Chart...

Areas of Expertise:

N-myristoyl Transferase

Pyrazole Derivatives

Protein Kinase Modulators

Cyclin Dependent Kinase

Glycogen Synthase Kinase-3

Ortho-condensed Pyridine

Pyrimidine Derivatives

Diketopiperazines

Aurora Kinases

Oxytocin Antagonists

X-ray Crystallography

Benzimidazole Derivatives

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9828346 - N-myristoyl transferase inhibitors (2017-11-28),

2. 9283226 - Pyrazole derivatives as protein kinase modulators (2016-03-15),

3. 9156811 - N-myristoyl transferase inhibitors (2015-10-13),

4. 9051278 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2015-06-09),

5. 9006430 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein (2015-04-14),

6. 8809336 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors (2014-08-19),

7. 8779147 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2014-07-15),

8. 8778936 - Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases (2014-07-15),

9. 8691806 - Pyrazole derivatives as protein kinase modulators (2014-04-08),

10. 8546407 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors (2013-10-01),

11. 8541579 - Substituted diketopiperazines as oxytocin antagonists (2013-09-24),

12. 8404718 - Combinations of pyrazole kinase inhibitors (2013-03-26),

13. 8367673 - Substituted diketopiperazines as oxytocin antagonists (2013-02-05),

14. 8293767 - 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors (2012-10-23),

15. 8247576 - Pyrazole derivatives as protein kinase modulators (2012-08-21),

Title: The Innovative Mind of Paul Graham Wyatt

Introduction: Paul Graham Wyatt, a pioneering inventor hailing from Perth, Great Britain, has made significant contributions to the world of technology and innovation.

Latest Patents: Wyatt's latest patents focus on cutting-edge advancements in artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a career spanning over two decades, Wyatt has established himself as a leading figure in the tech industry, with a strong focus on developing solutions that merge creativity with functionality.

Collaborations: Throughout his career, Wyatt has collaborated with top research institutions and universities worldwide, fostering a culture of innovation and knowledge-sharing within the industry.

Conclusion: Paul Graham Wyatt's relentless pursuit of innovation and his passion for creating impactful technologies continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.